Danimer Scientific (DNMR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined to $7.6 million, mainly due to lower PHA and PLA sales impacted by Starbucks inventory adjustments and the Ukraine conflict.

• PHA-based products comprised 81% of product revenue, but overall sales and service revenues fell due to customer reallocations and geopolitical impacts.

• Cost reduction initiatives included workforce reductions, curtailment of non-core R&D, and suspension of Danimer Catalytic Technologies, with total annualized cost reductions exceeding $20 million since 2022.

• CEO announced retirement, with transition support and search for successor underway.

• Pro-rata warrant dividend program completed, enabling $6.1 million in convertible notes retired and providing further deleveraging opportunities.

Financial highlights

• Q2 2024 revenue was $7.6 million, down from $12.9 million year-over-year; net loss for Q2 was $22.7 million, improved from $39.2 million prior year.

• Adjusted EBITDA loss for Q2 2024 was $9.9 million, improved from $10.2 million prior year.

• Adjusted gross loss for Q2 2024 was $1.8 million, similar to $1.6 million prior year.

• Cash and cash equivalents at June 30, 2024, were $40.3 million; working capital was $27.4 million.

• Total debt at June 30, 2024, was $393.9 million, including $45.7 million in low-interest loans expected to be forgiven starting 2026.

Outlook and guidance

• Adjusted EBITDA for 2024 expected between $(30) million and $(35) million, reflecting ongoing inventory and customer launch timing impacts.

• CapEx guidance unchanged at $8–$10 million for 2024, focused on Bainbridge facility and maintenance.

• Year-end liquidity projected at $15–$20 million, including cash and credit facility availability.

• PHA revenues are forecast to more than triple by end of Q2 2025, driven by a 20-million-pound cutlery award and current customer demand.

• Positive EBITDA expected in Q2 2025, with a $15 million annualized run rate by year-end 2025.